Fuchs, T. L. et al. Assessment of tumor-infiltrating lymphocytes using International TILs Working Group (ITWG) system is a strong predictor of overall survival in colorectal carcinoma: a study of 1034 patients. Am. J. Surg. Pathol. 44, 536–544 (2020).
Luen, S. J. et al. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol. 18, 52–62 (2017).
Hwang, C. et al. Stromal tumor-infiltrating lymphocytes evaluated on H&E-stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma. Oncol. Lett. 17, 4557–4565 (2019).
Paijens, S. T., Vledder, A., de Bruyn, M. & Nijman, H. W. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol. Immunol. 18, 842–859 (2021).
Zhang, J., Huang, D., Saw, P. E. & Song, E. Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends Immunol. 43, 523–545 (2022).
Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).
June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018).
Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).
Dong, X. et al. Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice. J. Immunother. Cancer 11, e005583 (2023).
Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).
Eshhar, Z., Waks, T., Gross, G. & Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl Acad. Sci. USA 90, 720–724 (1993).
Globerson Levin, A., Rivière, I., Eshhar, Z. & Sadelain, M. CAR T cells: building on the CD19 paradigm. Eur. J. Immunol. 51, 2151–2163 (2021).
Reddy, N. R. et al. Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs. Science 386, eadl4793 (2024).
Simic, M. S. et al. Programming tissue-sensing T cells that deliver therapies to the brain. Science 386, eadl4237 (2024).
Mohammed, S. et al. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol. Ther. 25, 249–258 (2017).
Kloss, C. C. et al. Dominant-negative TGF-β receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol. Ther. 26, 1855–1866 (2018).
Rafiq, S. et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat. Biotechnol. 36, 847–856 (2018).
Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293–300 (2019).
Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR t-cell therapy. Cancer Discov. 8, 1219–1226 (2018).
Berraondo, P. et al. Cytokines in clinical cancer immunotherapy. Br. J. Cancer 120, 6–15 (2019).
Kim, B. G., Malek, E., Choi, S. H., Ignatz-Hoover, J. J. & Driscoll, J. J. Novel therapies emerging in oncology to target the TGF-β pathway. J. Hematol. Oncol. 14, 55 (2021).
Medzhitov, R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1, 135–145 (2001).
Tugues, S. et al. New insights into IL-12-mediated tumor suppression. Cell Death Differ. 22, 237–246 (2015).
Pegram, H. J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133–4141 (2012).
Canelo-Vilaseca, M. et al. Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma. Bone Marrow Transpl. 60, 559–567 (2025).
Pegram, H. J. et al. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia 29, 415–422 (2015).
Cordas dos Santos, D. M. et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat. Med. 30, 2667–2678 (2024).
Aithal, A. et al. MUC16 as a novel target for cancer therapy. Expert Opin. Ther. Targets 22, 675–686 (2018).
Yeku, O. O., Purdon, T. J., Koneru, M., Spriggs, D. & Brentjens, R. J. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci. Rep. 7, 10541 (2017).
Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S. & Brentjens, R. J. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology 4, e994446 (2015).
Zou, J. J. et al. Structure-function analysis of the p35 subunit of mouse interleukin 12. J. Biol. Chem. 270, 5864–5871 (1995).
Koneru, M., O’Cearbhaill, R., Pendharkar, S., Spriggs, D. R. & Brentjens, R. J. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J. Transl. Med. 13, 102 (2015).
O’Cearbhaill, R. E. et al. A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC). Gynecol. Oncol. 159 (Suppl. 1), 42 (2020).
Etxeberria, I. et al. Intratumor adoptive transfer of IL-12 mRNA transiently engineered antitumor CD8+ T cells. Cancer Cell 36, 613–629.e617 (2019).
Jia, Z. et al. IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines. Front. Immunol. 13, 952231 (2022).
Hu, J. et al. Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. J. Immunother. Cancer 10, e003633 (2022).
Atsavapranee, E. S., Billingsley, M. M. & Mitchell, M. J. Delivery technologies for T cell gene editing: applications in cancer immunotherapy. EBioMedicine 67, 103354 (2021).
Vaeth, M. & Feske, S. NFAT control of immune function: new frontiers for an abiding trooper. F1000Res 7, 260 (2018).
Yang, Y. et al. Inducible expression of interleukin-12 augments the efficacy of affinity-tuned chimeric antigen receptors in murine solid tumor models. Nat. Commun. 14, 2068 (2023).
Liu, Y. et al. Armored inducible expression of il-12 enhances antitumor activity of glypican-3-targeted chimeric antigen receptor-engineered T cells in hepatocellular carcinoma. J. Immunol. 203, 198–207 (2019).
Kunert, A. et al. Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors. Oncoimmunology 7, e1378842 (2017).
Zhang, L. et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin. Cancer Res. 21, 2278–2288 (2015).
Guo, T., Ma, D. & Lu, T. K. Sense-and-Respond payload delivery using a novel antigen-inducible promoter improves suboptimal car-t activation. ACS Synth. Biol. 11, 1440–1453 (2022).
Sachdeva, M. et al. Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality. Nat. Commun. 10, 5100 (2019).
Chen, A. X. Y. et al. Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery. Nature 644, 241–251 (2025). Genes that are highly expressed in intratumoural T cells relative to splenic T cells are used to rationally select the promoters NR4A2 and RGS16 for tumour-localized induction of cytokine payloads. This enhanced CAR T cell efficacy and safety across multiple solid tumour models.
Ghayur, T. et al. Caspase-1 processes IFNγ-inducing factor and regulates LPS-induced IFNγ production. Nature 386, 619–623 (1997).
Fantuzzi, G., Puren, A. J., Harding, M. W., Livingston, D. J. & Dinarello, C. A. Interleukin-18 regulation of interferon gamma production and cell proliferation as shown in interleukin-1beta-converting enzyme (caspase-1)-deficient mice. Blood 91, 2118–2125 (1998).
Tsutsumi, N. et al. The structural basis for receptor recognition of human interleukin-18. Nat. Commun. 5, 5340 (2014).
Ihim, S. A. et al. Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: biological role in induction, regulation, and treatment. Front. Immunol. 13, 919973 (2022).
Jaspers, J. E. et al. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. J. Clin. Invest. 133, e166028 (2023).
Hu, B. et al. Augmentation of antitumor immunity by human and mouse car T cells secreting IL-18. Cell Rep. 20, 3025–3033 (2017).
Avanzi, M. P. et al. Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. Cell Rep. 23, 2130–2141 (2018).
Ng, B. D. et al. IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model. Blood 144, 171–186 (2024).
Glienke, W. et al. GMP-compliant manufacturing of TRUCKs: car T cells targeting GD(2) and releasing inducible IL-18. Front. Immunol. 13, 839783 (2022).
Fischer-Riepe, L. et al. Preclinical development of CAR T cells with antigen-inducible IL18 enforcement to treat GD2-positive solid cancers. Clin. Cancer Res. 30, 3564–3577 (2024).
Svoboda, J. et al. Enhanced CAR T-cell therapy for lymphoma after previous failure. N. Engl. J. Med. 392, 1824–1835 (2025). Here, IL-18 armoured CD19 CAR T cells are shown to be safe for patients with relapsed or refractory lymphoma who have previously received unarmoured CD19 CAR T cell therapy. For the 21 patients enrolled, complete and partial response rates at 3 months post-infusion were 52% and 29%, respectively.
Geyer, M. B. et al. CD371-targeted CAR T-cells secreting interleukin-18 exhibit robust expansion and disease clearance in patients with refractory acute myeloid leukemia. Blood 144, 2070 (2024).
Kessel, C., Rossig, C. & Abken, H. Weal and woe of interleukin-18 in the T cell therapy of cancer. J. Immunother. Cancer 13, e010545 (2025).
Shouse, A. N., LaPorte, K. M. & Malek, T. R. Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer. Immunity 57, 414–428 (2024).
Chinen, T. et al. An essential role for the IL-2 receptor in Treg cell function. Nat. Immunol. 17, 1322–1333 (2016).
Yi, X. M., Lian, H. & Li, S. Signaling and functions of interleukin-33 in immune regulation and diseases. Cell Insight 1, 100042 (2022).
Brog, R. A. et al. Superkine IL-2 and IL-33 armored CAR T cells reshape the tumor microenvironment and reduce growth of multiple solid tumors. Cancer Immunol. Res. 10, 962–977 (2022).
Krueger, J. G. et al. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front. Immunol. 15, 1331217 (2024).
Wertheimer, T. et al. IL-23 stabilizes an effector Treg cell program in the tumor microenvironment. Nat. Immunol. 25, 512–524 (2024).
Ma, X. et al. Interleukin-23 engineering improves CAR T cell function in solid tumors. Nat. Biotechnol. 38, 448–459 (2020).
Chen, D., Tang, T. X., Deng, H., Yang, X. P. & Tang, Z. H. Interleukin-7 biology and its effects on immune cells: mediator of generation, differentiation, survival, and homeostasis. Front. Immunol. 12, 747324 (2021).
Link, A. et al. Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. Nat. Immunol. 8, 1255–1265 (2007).
Li, L. et al. Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells. Sci. Rep. 12, 12506 (2022).
Markley, J. C. & Sadelain, M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 115, 3508–3519 (2010).
Wu, H. et al. Interleukin-7 expression by CAR-T cells improves CAR-T cell survival and efficacy in chordoma. Cancer Immunol. Immunother. 73, 188 (2024).
Lu, L. L. et al. GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy. Cell Biol. Toxicol. 39, 3101–3119 (2023).
Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359–371 (2023).
Brown, C. E. et al. Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat. Med. 30, 1001–1012 (2024).
Adachi, K. et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat. Biotechnol. 36, 346–351 (2018).
Yan, Y. et al. CCL19 and CCR7 expression, signaling pathways, and adjuvant functions in viral infection and prevention. Front. Cell Dev. Biol. 7, 212 (2019).
Goto, S. et al. Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models. Cancer Immunol. Immunother. 70, 2503–2515 (2021).
Pang, N. et al. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J. Hematol. Oncol. 14, 118 (2021).
Nakajima, T. E. et al. Updated results from first-in-human phase 1 dose-escalation trial of TAK-102, a GPC3-targeted armored CAR T cells, in patients with advanced solid tumors. J. Clin. Oncol. 42, 2543 (2024).
Lei, W. et al. Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma. Cell Discov. 10, 5 (2024).
Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma. N. Engl. J. Med. 380, 45–56 (2019).
Leen, A. M. et al. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol. Ther. 22, 1211–1220 (2014).
Weimin, S., Abula, A., Qianghong, D. & Wenguang, W. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression. Cancer Biol. Ther. 21, 570–580 (2020).
Noh, K. E. et al. TGF-β/IL-7 chimeric switch receptor-expressing car-t cells inhibit recurrence of cd19-positive b cell lymphoma. Int. J. Mol. Sci. 22, 8706 (2021).
Perera, P. Y., Lichy, J. H., Waldmann, T. A. & Perera, L. P. The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. Microbes Infect. 14, 247–261 (2012).
Cai, M. et al. Research progress of interleukin-15 in cancer immunotherapy. Front. Pharmacol. 14, 1184703 (2023).
Shi, H. et al. IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models. Front. Immunol. 14, 1165404 (2023).
Lanitis, E. et al. Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. J. Exp. Med. 218, e20192203 (2021).
Zhang, Y. et al. Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy. J. Transl. Med. 20, 432 (2022).
Gargett, T. et al. GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma. J. Immunother. Cancer 10, e005187 (2022).
Ataca Atilla, P. et al. Modulating TNFα activity allows transgenic IL15-expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J. Immunother. Cancer 8, e001229 (2020).
Nguyen, R. et al. Cooperative armoring of CAR and TCR T cells by T cell-restricted IL15 and IL21 universally enhances solid tumor efficacy. Clin. Cancer Res. 30, 1555–1566 (2024).
Steffin, D. et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature 637, 940–946 (2024). The antitumour efficacy of GPC3-targeted CAR T cells towards solid tumours is shown to be dependent on co-expression of IL-15 in phase I clinical trials in adult or paediatric patients and it is shown that inducible safety switches can be implemented to successfully mitigate toxicities.
Saraiva, M., Vieira, P. & O’Garra, A. Biology and therapeutic potential of interleukin-10. J. Exp. Med. 217, e20190418 (2020).
Saraiva, M. & O’Garra, A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10, 170–181 (2010).
Carlini, V. et al. The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. Front. Immunol. 14, 1161067 (2023).
Zhao, Y. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat. Biotechnol. 42, 1693–1704 (2024).
Piechocki, M. P., Ho, Y. S., Pilon, S. & Wei, W. Z. Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J. Immunol. 171, 5787–5794 (2003).
Yong, C. S. et al. Embryonic lethality in homozygous human Her-2 transgenic mice due to disruption of the Pds5b gene. PLoS ONE 10, e0136817 (2015).
Guo, Y. et al. IL-10 expressing CD19 CAR-T cells induce complete remission and improve long-term protection in relapsed or refractory B-Cell Hematological malignancies. Blood 144, 92–92 (2024).
Li, H. S. et al. Multidimensional control of therapeutic human cell function with synthetic gene circuits. Science 378, 1227–1234 (2022).
Webber, B. R. et al. Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repair. Nat. Biomed. Eng. 8, 1553–1570 (2024).
Roybal, K. T. et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell 167, 419–432.e416 (2016). The first demonstration that the synNotch system can be used to restrict antitumour responses to the tumour site based on the requirement for antigen detection, inspiring further development of logic-gated, armoured T cell therapies.
Zhu, I. et al. Modular design of synthetic receptors for programmed gene regulation in cell therapies. Cell 185, 1431–1443.e1416 (2022).
Luo, H. et al. Target-dependent expression of IL12 by synNotch receptor-engineered NK92 cells increases the antitumor activities of CAR-T cells. Front. Oncol. 9, 1448 (2019).
Allen, G. M. et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science 378, eaba1624 (2022).
Choe, J. H. et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci. Transl. Med. 13, eabe7378 (2021).
Srivastava, S. et al. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell 35, 489–503.e488 (2019).
Hyrenius-Wittsten, A. et al. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci. Transl. Med. 13, eabd8836 (2021).
Hernandez-Lopez, R. A. et al. T cell circuits that sense antigen density with an ultrasensitive threshold. Science 371, 1166–1171 (2021).
Piraner, D. I. et al. Engineered receptors for soluble cellular communication and disease sensing. Nature 638, 805–813 (2025).
Yang, Z. et al. Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment. J. Transl. Med. 21, 158 (2023).
Das, D., Dey, S., Brewster, R. C. & Choubey, S. Effect of transcription factor resource sharing on gene expression noise. PLoS Comput. Biol. 13, e1005491 (2017).
Reichenbach, P. et al. A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor. Nat. Biomed. Eng. 7, 1063–1080 (2023).
Liu, Z. et al. Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector. Sci. Rep. 7, 2193 (2017).
Ayala Ceja, M., Khericha, M., Harris, C. M., Puig-Saus, C. & Chen, Y. Y. CAR-T cell manufacturing: major process parameters and next-generation strategies. J. Exp. Med. 221, e20230903 (2024).
Sloas, D. C., Tran, J. C., Marzilli, A. M. & Ngo, J. T. Tension-tuned receptors for synthetic mechanotransduction and intercellular force detection. Nat. Biotechnol. 41, 1287–1295 (2023).